Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-3467 Alone and in Combination with Olaparib in Participants with Advanced Solid Tumors (POLAR Trial)

Next Previous
X
Search
Trial Profile

Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-3467 Alone and in Combination with Olaparib in Participants with Advanced Solid Tumors (POLAR Trial)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olaparib (Primary) ; RP-3467 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms POLAR
  • Sponsors Repare Therapeutics

    • Most Recent Events

    • 09 Jan 2025 According to a Repare Therapeutics media release, Topline safety, tolerability and early efficacy data from this trial expected in Q3 2025.
    • 14 Oct 2024 According to a Repare Therapeutics media release, the first patient has been dosed in this study.
    • 14 Oct 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top